In a strategic move to bolster its financial position, SoftOx Solutions AS, a pioneering medtech company based in Oslo, Norway, has announced a significant development in its funding strategy. The company, which specializes in the health care sector with a focus on pharmaceuticals, has secured a private placement of shares in a financing transaction with Long State Investments Limited. This decision, approved by the board, aims to enhance the company’s share capital through the issuance of new shares at a nominal value.
SoftOx Solutions AS, founded in 2012, has carved a niche for itself in the pharmaceutical industry with its innovative SoftOx technology. This groundbreaking technology is designed to eradicate microorganisms in biofilms by targeting various components of microbes. Its application is particularly effective in preventing and treating infections on breached or compromised skin, including acute wounds and skin lesions in patients with eczema. The company is currently advancing two key products: the SoftOx Wound Irrigation Solution and the SoftOx Biofilm Eradicator. Both products are in preclinical studies, focusing on the prevention and treatment of infections on compromised skin and addressing biofilm infections in non-healing chronic wounds, respectively.
The decision to proceed with a private placement, foregoing the usual preferential rights, underscores the company’s commitment to securing timely funding. This approach is deemed essential for SoftOx Solutions AS to continue its development trajectory without the immediate need for a subsequent public offering. The transaction includes a placement commission for Long State, executed under the terms of the Equity Placement Agreement, reflecting a strategic partnership aimed at propelling the company forward.
Trading on the Frankfurt Stock Exchange, SoftOx Solutions AS has demonstrated resilience in a challenging market environment. Despite a negative price-earnings ratio of -10.14 and a close price of 0.004 EUR as of April 9, 2026, the company’s market capitalization stands at 293,460,000 EUR. This financial landscape is marked by a 52-week high of 0.05 EUR and a low of 0.003 EUR, illustrating the volatility and potential within the sector.
Beyond its financial maneuvers, SoftOx Solutions AS continues to forge ahead in its mission to develop pan-antimicrobial drugs. Collaborating with Nordic research institutions, the company is at the forefront of clinical-stage pharmaceutical development. Its efforts are not only aimed at addressing current challenges in infection prevention and treatment but also at setting new standards in the health care sector.
As SoftOx Solutions AS navigates through its strategic funding and product development phases, its role in the pharmaceutical industry remains pivotal. With a focus on innovation and collaboration, the company is poised to make significant contributions to the field of health care, particularly in the realm of infection prevention and treatment. The private placement with Long State Investments Limited marks a critical step in this journey, providing the necessary capital to fuel further research, development, and ultimately, the realization of its vision for a healthier future.
